Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result
Kidney cancer
Cabozantinib (VEGFR/MET/AXL TKI) + nivolumab/ipilimumab extends PFS—but no OS gain—in 1L advanced ccRCC (COSMIC-313)
Cabozantinib, a multi-kinase TKI targeting VEGFR/MET/AXL, was added to nivolumab (PD-1) + ipilimumab (CTLA-4) in the double-blind Phase III COSMIC-313 trial (NCT03937219) in previously untreated advanced clear cell…
NCT03937219 - Trial result
Kidney cancer
Belzutifan (HIF-2α inhibitor) + Lenvatinib (VEGFR TKI) Extends PFS vs Cabozantinib in Post–PD-(L)1 ccRCC (LITESPARK-011)
Belzutifan is an oral HIF-2α inhibitor and lenvatinib is an oral multikinase VEGFR TKI; this open-label Phase 3 trial (LITESPARK-011; NCT04586231) randomized previously treated advanced clear-cell RCC after…
NCT04586231 - Trial result
Lymphoma
Nivolumab (PD-1) + AVD Delivers 2-year PFS ~78% in HIV-Associated Advanced cHL (S1826 subset)
Nivolumab is a PD-1 checkpoint inhibitor combined here with AVD chemotherapy (doxorubicin, vinblastine, dacarbazine) and was tested against brentuximab vedotin (CD30-directed ADC) + AVD in the international Phase 3…
NCT03907488 - Trial result
Ovarian cancer
Darolutamide (AR antagonist) + leuprolide + exemestane misses ORR bar but delivers 8.5-mo mPFS in AI-refractory recurrent AGCT
Darolutamide is an androgen receptor (AR) antagonist combined here with ovarian suppression (leuprolide acetate, a GnRH agonist) and estrogen blockade (exemestane, a steroidal aromatase inhibitor) in a single-arm…
NCT06169124 - Trial result Spotlight
Stomach and esophageal cancer
ONO-4578 (EP4/PGE2-axis antagonist) + nivolumab + oxaliplatin chemo improves PFS in 1L HER2-negative gastric/GEJ cancer
ONO-4578 is an oral, selective EP4 antagonist designed to blunt PGE2-driven tumor immunosuppression and potentially deepen anti–PD-1 activity when combined with nivolumab. In this multicenter, double-blind,…
- Trial result Spotlight
Neuroendocrine and adrenal tumors
¹⁷⁷Lu-DOTATATE (SSTR-targeted PRRT) extends PFS ~14 months vs high-dose octreotide in 1L G2–G3 GEP-NETs
¹⁷⁷Lu-DOTATATE is a radiolabeled somatostatin analog (PRRT) that targets somatostatin receptor–positive (SSTR+) disease; in the open-label, randomized Phase 3 NETTER-2 trial (NCT03972488), previously untreated…
NCT03972488 - Trial result
Bladder and urothelial cancer
Erdafitinib (FGFR1–4 inhibitor) Extends OS vs Chemo in FGFR3‑Altered Metastatic Urothelial Cancer
Erdafitinib (Balversa) is an oral pan‑FGFR tyrosine kinase inhibitor targeting susceptible FGFR3 alterations and was evaluated in THOR/BLC3001 Cohort 1 (NCT03390504), an open‑label Phase 3 trial in previously treated…
NCT03390504 - Trial result
Chronic myeloid leukemia
Asciminib (STAMP inhibitor; BCR::ABL1 myristoyl-pocket) beats flumatinib in 1L CML-CP on EMR/MMR and AE discontinuations (China MAIC)
Asciminib is a first-in-class STAMP BCR::ABL1 inhibitor (myristoyl-pocket binder), indirectly compared vs flumatinib (an ATP-competitive 2G TKI used mainly in China) using an anchored matching-adjusted indirect…
NCT04971226 - New trial Spotlight
Stomach and esophageal cancer
Phase 3 cadonilimab PD-1×CTLA-4 bispecific antibody + CAPOX vs CAPOX ± nivolumab in 1L HER2-negative gastric/GEJ
Akeso’s randomized, double-blind, multi-regional Phase 3 trial (NCT07700979) tests whether adding cadonilimab—a PD-1 (CD279) and CTLA-4 dual-targeting bispecific antibody—improves overall survival versus a control…
NCT07700979 Registrational - New trial
Pancreatic cancer
Phase 1 XNW28012 tissue factor–targeted topo1 inhibitor ADC in metastatic pancreatic cancer
Evopoint Biosciences’ Phase 1, open-label, randomized, multicenter study tests XNW28012 monotherapy in metastatic pancreatic cancer that has progressed after prior therapy, with two IV Q3W dose levels (2.0 mg/kg vs…
NCT07707674 Exploratory - New trial
Stomach and esophageal cancer
Phase 1/2 ifinatamab deruxtecan (B7-H3 topo-I ADC) in 2L/3L ESCC
This Phase 1/2 open-label KEYMAKER-U06 umbrella platform substudy evaluates ifinatamab deruxtecan (I-DXd; DS-7300a) in participants with unresectable locally advanced or metastatic esophageal squamous cell carcinoma…
NCT07405151 Exploratory - New trial
Prostate cancer
Phase 2 zanzalintinib (MET/VEGFR2/AXL/MER TKI) in aggressive-variant prostate cancer
This multicenter, single-arm Phase 2 NAPOLEON study evaluates the antitumor activity of oral zanzalintinib 60 mg once daily in men with aggressive variant prostate cancer (AVPC), using a 2‑stage group-sequential…
NCT07218666 Exploratory - New trial
Brain and CNS tumors
Phase 2 zanzalintinib MET/VEGFR/AXL/MER inhibitor in metastatic pheochromocytoma/paragangliom
This Phase 2, single-arm study at Dana-Farber Cancer Institute evaluates oral once-daily zanzalintinib (XL092) in patients with unresectable, progressive metastatic pheochromocytoma or paraganglioma (PPGL).…
NCT07714551 Exploratory - New trial
Neuroendocrine and adrenal tumors
Phase 2 ivonescimab PD-1×VEGF bispecific antibody in previously treated ACC/PPGL
This Phase 2, open-label, multi-cohort study at MD Anderson Cancer Center evaluates ivonescimab given intravenously every 3 weeks in two rare endocrine malignancy populations: unresectable/metastatic adrenocortical…
NCT07743138 Exploratory - New trial
Brain and CNS tumors
Phase 1b NLG802 (indoximod prodrug; IDO/TDO-pathway immunometabolic modulator) + temozolomide in pediatric CNS tumors
This open-label Phase 1b, dose-escalation study evaluates escalating oral NLG802 (a prodrug of indoximod) given with oral temozolomide in children with relapsed/refractory primary brain and/or spinal tumors, aiming…
NCT07732413 Exploratory - New trial Spotlight
Liver and bile duct cancer
Phase 2 zolbetuximab CLDN18.2-directed monoclonal antibody + CAPOX/mFOLFOX6 in BTC
Single-arm Phase 2 at the University of Alabama at Birmingham evaluates zolbetuximab, a CLDN18.2-targeted monoclonal antibody that can drive tumor cell killing via immune effector mechanisms (including ADCC and…
NCT07723534 Exploratory - New trial Spotlight
Multiple solid tumors
Phase 1/2 ARV-6723 oral PROTAC HPK1 degrader ± pembrolizumab (PD-1 mAb) in solid tumors
This first-in-human, open-label Phase 1/2 study sponsored by Arvinas evaluates ARV-6723 as monotherapy and combined with pembrolizumab (Merck/MSD’s anti–PD-1 monoclonal antibody) in adults with advanced/metastatic,…
NCT07749586 First-in-human - Trial result
Multiple myeloma
Linvoseltamab (BCMA×CD3 bispecific) shows sustained HRQoL gains (pain/fatigue) in triple-class–exposed R/R myeloma
Linvoseltamab is an off-the-shelf T-cell–engaging BCMA×CD3 bispecific antibody evaluated in LINKER-MM1 (Phase I/II; NCT03761108) in triple-class–exposed relapsed/refractory multiple myeloma (n=117; median follow-up…
NCT03761108 - Trial result
Colorectal cancer
High-dose vitamin D3 (cholecalciferol) add-on fails to move the needle on PFS in 1L mCRC (SOLARIS)
Vitamin D3 (cholecalciferol) supplementation was tested as a non-oncologic add-on to standard first-line mCRC therapy—mFOLFOX6 or FOLFIRI plus bevacizumab—in the US-based, double-blind SOLARIS Phase 3 trial…
NCT04094688 - Trial result
Non-small cell lung cancer
Tiragolumab (anti‑TIGIT) + Atezolizumab Fails to Beat Durvalumab for PFS in Stage III NSCLC Consolidation
SKYSCRAPER-03 (Phase III, open-label; NCT04513925) tested tiragolumab, a TIGIT-checkpoint monoclonal antibody, plus atezolizumab (PD‑L1 inhibitor) as post–platinum concurrent chemoradiation consolidation versus…
NCT04513925 - Trial result Spotlight
Lymphoma
Epcoritamab (CD3×CD20 bispecific) + BR delivers 96% CR and 83% 3-year PFS in 1L follicular lymphoma
Epcoritamab is a subcutaneous CD3×CD20 T-cell–engaging bispecific antibody; in EPCORE NHL-2 arm 3 (Phase 1b/2; NCT04663347), it was combined with first-line bendamustine+rituximab (BR) followed by epcoritamab…
NCT04663347 - New trial Spotlight
Prostate cancer
Phase 1 FX-111 ARON degrader targets transcriptionally active androgen receptor in mCRPC.
This Phase 1, first-in-human, open-label dose-escalation with optional expansion study evaluates FX-111 in adult men with metastatic castration-resistant prostate adenocarcinoma that has progressed on…
NCT07719361 First-in-human - New trial
Prostate cancer
Early Phase 1 semaglutide GLP-1 receptor agonist neoadjuvant metabolic therapy before prostatectomy
Banner Health’s single-arm, open-label exploratory early phase 1 study tests whether preoperative semaglutide can drive measurable biologic changes in intermediate-risk localized prostate cancer during a 3–6 month…
NCT07727473 Exploratory - New trial Spotlight
Colorectal cancer
Phase 2 botensilimab CTLA-4 antibody + balstilimab PD-1 antibody in early MSS rectal cancer.
This prospective, multi-site, non-randomized Phase 2 study (RECTIFY-1) tests neoadjuvant dual-checkpoint blockade in early, resectable rectal adenocarcinoma that is microsatellite stable / mismatch repair proficient…
NCT07735624 Exploratory - New trial
Breast cancer
Phase 2 neratinib pan-HER (EGFR/HER2/HER4) TKI added to endocrine therapy in ER+/HER2- breast cancer.
This single-center, randomized Phase 2 UC San Diego study tests whether adding neratinib (an oral, irreversible pan-HER tyrosine kinase inhibitor targeting EGFR/HER2/HER4) can improve disease control when layered…
NCT07729046 Exploratory - New trial
Uterine (endometrial) cancer
Phase 2 OK-1 (SHetA2) Grp78/Hsc70/mortalin inhibitor plus weekly paclitaxel in recurrent endometrial cancer
This single-arm Phase 2 study with a safety lead-in tests whether adding OK-1 to weekly paclitaxel can reduce tumor burden in patients with measurable advanced or recurrent endometrial cancer after prior…
NCT07737795 Exploratory - New trial Spotlight
Lymphoma
Phase 2/3 MK-1045 CD19×CD3 bispecific antibody plus rituximab (CD20 mAb) in 1L FL.
Merck Sharp & Dohme (MSD) is running a Phase 2/3, randomized, open-label study testing MK-1045 + rituximab (or a rituximab biosimilar) versus physician’s choice chemoimmunotherapy in previously untreated classical…
NCT07634471 Registrational - New trial
Brain and CNS tumors
Phase 2 WSD0922-FU EGFR/EGFRvIII inhibitor plus adjuvant temozolomide in EGFR-mutant glioblastoma.
This randomized Phase 2 Mayo Clinic study tests whether adding WSD0922-FU—an oral, CNS-penetrant small-molecule inhibitor of EGFR and EGFRvIII—improves outcomes when combined with adjuvant temozolomide (an alkylating…
NCT07708961 Exploratory - New trial
Head and neck cancer
Phase 2 RiMO-301 hafnium-based MOF radiosensitizer + pembrolizumab (PD-1) with neoadjuvant RT in HNC.
This Phase 2 neoadjuvant study at the University of Illinois Chicago tests whether adding intratumoral RiMO-301—a hafnium-based nanoscale metal–organic framework (MOF) radio-enhancer that increases local radiation…
NCT07732634 Exploratory - New trial
Lymphoma
Phase 1b teclistamab BCMA×CD3 bispecific T‑cell engager in relapsed/refractory plasmablastic lymphoma.
This Phase 1b, open-label, dose-finding and expansion study sponsored by the National Cancer Institute evaluates subcutaneous teclistamab for patients with relapsed/refractory plasmablastic lymphoma after at least 1…
NCT07332507 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.